Skip to Content

Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

Download PQI pdf 0.21MB

Last Updated: October 10, 2023

By: Jeff Engle, PharmD, MS

About this PQI

This PQI will discuss effective management of adverse effects of sorafenib in the treatment of hepatocellular carcinoma and discuss data supporting the sequencing of patients to second-line therapy with regorafenib for increased survival benefit.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI